Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiocyanic Acid SCHEMBL6909048 | 0.93 | MAPT (0.52) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL21027662 | 0.93 | MAPT (0.52) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL20861898 | 0.93 | MAPT (0.52) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL24296678 | 0.89 | ALDH1A1 (0.48) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL4408306 | 0.86 | ALDH1A1 (0.64) | MAPTALDH1A1CA2CA5APOLB | |
| SCHEMBL21632569 | 0.82 | MAPT (0.43) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL19605694 | 0.79 | MAPT (0.58) | MAPTALDH1A1CA2CA5APOLB | |
| SCHEMBL25056632 | 0.78 | ALDH1A1 (0.40) | MAPTALDH1A1CA2CA5APOLB | |
| SCHEMBL25056669 | 0.76 | ALDH1A1 (0.38) | MAPTALDH1A1CA2CA5ACYP2A6 | |
| SCHEMBL1119058 | 0.76 | ACHE (0.44) | MAPTALDH1A1CA2CYP2A6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263962-A1 | COPOLYMER HYBRID AEROGELS BASED ON ISOCYANATE - CYCLIC ETHER - CLAY NETWORKS | Henkel IP & Holding GmbH (DE) | 2019-08-29 | — | — | US | claimed |
| US-20230399942-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-12-14 | — | — | US | disclosed |
| WO-2023164002-A1 | ELECTROLYTE ADDITIVE COMPOUNDS FOR HIGH VOLTAGE ENERGY STORAGE DEVICE, AND ASSOCIATED PROCESSES | TESLA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-116355117-A | Terminal functionalized high cis-rare earth conjugated diene rubber and preparation method thereof | 青岛科技大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3227272-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2021-07-07 | — | — | EP | disclosed |
| US-10770792-B2 | Scanning antenna | SHARP KABUSHIKI KAISHA (JP) | 2020-09-08 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2020133403-A1 | SUBSTITUTED PYRIMIDINE ARYL ESTER DERIVATIVE, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | 青岛清原化合物有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| CN-1816531-A | Process for the preparation of aryl alkyl acid derivatives and their use for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-08-09 | — | — | CN | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| CN-1158315-C | Process for producing ethylene/olefin interpolymers | 伊斯曼化学公司 | 2004-07-21 | — | — | CN | disclosed |
| CN-1367800-A | Process for producing ethylene/olefin interpolymers | EASTMAN CHEM CO (US) | 2002-09-04 | — | — | CN | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| EP-0816339-B1 | Process for the preparation of (+-)2-Azabicyclo[2.2.1]hept-5-en-3-one | DEGUSSA (DE) | 2002-01-16 | — | — | EP | disclosed |
| EP-0816339-A2 | Process for the preparation of (+-)2-Azabicyclo[2.2.1]hept-5-en-3-one | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | MAPT 1983/4885ALDH1A1 2353/4885CA2 4188/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885ALDH1A1 199/4885CA2 4415/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885ALDH1A1 199/4885CA2 4415/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | MAPT 1155/4885ALDH1A1 448/4885CA2 1226/4885 |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | MAPT 1155/4885ALDH1A1 448/4885CA2 1226/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | MAPT 1370/4885ALDH1A1 2329/4885CA2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.